New hope for hard-to-treat hepatitis d: combo therapy targets stubborn infections

NCT ID NCT07128550

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 33 times

Summary

This study tests whether a combination of two experimental drugs (tobevibart and elebsiran) can clear or lower hepatitis D virus in adults who still have detectable virus despite taking bulevirtide. About 150 participants will receive the combination and be followed for up to 240 weeks to check safety and how well the virus is suppressed. The goal is to see if this new approach can achieve undetectable virus levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigative Site

    RECRUITING

    Innsbruck, 6020, Austria

  • Investigative Site

    RECRUITING

    Vienna, 1090, Austria

  • Investigative Site

    RECRUITING

    Bobigny, 93009, France

  • Investigative Site

    RECRUITING

    Clichy, 92110, France

  • Investigative Site

    RECRUITING

    Créteil, 94000, France

  • Investigative Site

    RECRUITING

    Le Chesnay, 78150, France

  • Investigative Site

    RECRUITING

    Limoges, 87000, France

  • Investigative Site

    RECRUITING

    Lyon, 69004, France

  • Investigative Site

    RECRUITING

    Montpellier, 34295, France

  • Investigative Site

    RECRUITING

    Pessac, 33604, France

  • Investigative Site

    RECRUITING

    Rennes, 35033, France

  • Investigative Site

    RECRUITING

    Toulouse, 31059, France

  • Investigative Site

    RECRUITING

    Villejuif, 94804, France

  • Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Investigative Site

    RECRUITING

    Frankfurt am Main, 60590, Germany

  • Investigative Site

    RECRUITING

    Hanover, 30625, Germany

  • Investigative Site

    RECRUITING

    Bergamo, 24127, Italy

  • Investigative Site

    RECRUITING

    Foggia, 71122, Italy

  • Investigative Site

    RECRUITING

    Milan, 20089, Italy

  • Investigative Site

    RECRUITING

    Milan, 20122, Italy

  • Investigative Site

    RECRUITING

    Pisa, 56124, Italy

  • Investigative Site

    RECRUITING

    Torino, 10122, Italy

  • Investigative Site

    RECRUITING

    Torino, 10126, Italy

  • Investigative Site

    RECRUITING

    Bucharest, 021105, Romania

  • Investigative Site

    RECRUITING

    Bucharest, 022328, Romania

  • Investigative Site

    RECRUITING

    Bucharest, 030303, Romania

  • Investigative Site

    RECRUITING

    Craiova, 200073, Romania

  • Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Investigative Site

    RECRUITING

    Barcelona, 08036, Spain

  • Investigative Site

    RECRUITING

    Madrid, 28007, Spain

  • Investigative Site

    RECRUITING

    Madrid, 28046, Spain

  • Investigative Site

    RECRUITING

    Santander, 39008, Spain

  • Investigative Site

    RECRUITING

    London, E1 1FR, United Kingdom

  • Investigative Site

    RECRUITING

    London, SE5 9NU, United Kingdom

  • Investigative Site

    RECRUITING

    London, W2 1NY, United Kingdom

  • Investigative Site

    RECRUITING

    Manchester, M8 5RB, United Kingdom

  • Investigative Site

    RECRUITING

    Nottingham, NG7 2UH, United Kingdom

Conditions

Explore the condition pages connected to this study.